| Hazard Information | Back Directory | [Uses]
SR33805 is a potent Ca2+ channel antagonist, with EC50s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca2+ channels. SR33805 can be used for the research of acute or chronic failing hearts[1][2]. | [in vivo]
SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats[2].
SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs[3]. | Animal Model: | Male Wistar rats (5 weeks) are subjected to coronary artery ligature[2] | | Dosage: | 0.2, 2, 20 mg/kg | | Administration: | A single i.p. injection | | Result: | Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg.
Did not affect other contractile parameters.
|
| [IC 50]
L-type calcium channel: 4.1 nM (EC50, in depolarized conditions); L-type calcium channel: 33 nM (EC50, in polarized conditions) | [storage]
Store at -20°C | [References]
[1] Romey G, et, al. Effects of two chemically related new Ca2+ channel antagonists, SR33557 (fantofarone) and SR33805, on the L-type cardiac channel. Eur J Pharmacol. 1994 Sep 22; 263(1-2): 101-5. DOI:10.1016/0014-2999(94)90529-0
[2] Mou YA, et, al. Beneficial effects of SR33805 in failing myocardium. Cardiovasc Res. 2011 Aug 1; 91(3): 412-9. DOI:10.1093/cvr/cvr096
[3] Hainaud P, et, al. The calcium inhibitor SR33805 reduces intimal formation following injury of the porcine carotid artery. Atherosclerosis. 2001 Feb 1; 154(2): 301-8. DOI:10.1016/s0021-9150(00)00487-1 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|